Please select the option that best describes you:
Which regimen do you prefer for patients with newly diagnosed DLBCL that are not candidates for doxorubicin secondary to low ejection fraction?
Do you use etoposide-based regimens such as R-CEPP? How about substitution with liposomal doxorubicin?
Answer from: Medical Oncologist at Community Practice
I like to use R-CEOP per Vancouver experience. Had very good results with it and is very well tolerated. I sometimes use it also in frail older patients who have normal EF. Etoposide substitutes doxorubicin in regimen: 50 mg/m2 on D1 and 100 mg/m2 PO on days 2-3 and can also give peg filgrastim on D...
Sign in or Register to read more